What's in Tranzyme, Inc.'s pipeline?

Tranzyme, Inc. has 3 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Tranzyme, Inc.'s portfolio?

Top competitors by shared drug class: SWOG Cancer Research Network.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/tranzyme-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Tranzyme, Inc. — Portfolio Competitive Intelligence Brief

Tranzyme, Inc. pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ulimorelin Invtravenously (IV)	Ulimorelin Invtravenously (IV)	phase 3	Ghrelin receptor agonist	Ghrelin receptor	Gastrointestinal
TZP-101	TZP-101	phase 3	Prodrug	H+/K+ ATPase	Gastrointestinal
Ulimorelin Intravenously (IV)	Ulimorelin Intravenously (IV)	phase 3	Ghrelin receptor agonist	Ghrelin receptor	Gastroenterology

Therapeutic area mix

Gastrointestinal · 2
Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

SWOG Cancer Research Network · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tranzyme, Inc.:

Cite this brief

Drug Landscape (2026). Tranzyme, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tranzyme-inc. Accessed 2026-05-14.